BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE)
Publication
, Conference
Teerlink, JR; Diaz, R; Felker, GM; McMurray, J; Metra, M; Solomon, SD; Legg, J; Varin, C; Kurtz, C; Malik, F; Abbasi, SA
Published in: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2020
Duke Scholars
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
EISSN
1558-3597
ISSN
0735-1097
Publication Date
2020
Volume
75
Issue
11
Start / End Page
754 / 754
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J., Metra, M., Solomon, S. D., … Abbasi, S. A. (2020). BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE). In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 75, pp. 754–754).
Teerlink, John R., Rafael Diaz, G Michael Felker, John McMurray, Marco Metra, Scott D. Solomon, Jason Legg, et al. “BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE).” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 75:754–754, 2020.
Teerlink JR, Diaz R, Felker GM, McMurray J, Metra M, Solomon SD, et al. BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE). In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2020. p. 754–754.
Teerlink, John R., et al. “BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE).” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 75, no. 11, 2020, pp. 754–754.
Teerlink JR, Diaz R, Felker GM, McMurray J, Metra M, Solomon SD, Legg J, Varin C, Kurtz C, Malik F, Abbasi SA. BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2020. p. 754–754.
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
EISSN
1558-3597
ISSN
0735-1097
Publication Date
2020
Volume
75
Issue
11
Start / End Page
754 / 754
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology